U.S. Markets open in 8 hrs 9 mins

Gilead price target raised to $100 from $89 at Lazard Capital

Lazard Capital raised its price target for Gilead citing increased confidence in the company's Hepatitis C virus franchise and reiterates a Buy rating on the stock.